Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1986 Dec 1;240(2):379–383. doi: 10.1042/bj2400379

Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

K F Tipton, J M McCrodden, M B Youdim
PMCID: PMC1147429  PMID: 3101671

Abstract

The compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces symptoms resembling Parkinson's disease in humans, acts both as a substrate and an enzyme-activated irreversible inhibitor of the B-form of monoamine oxidase from rat liver. Analysis of the inhibitory process showed the compound to be considerably more efficient as a substrate than as an irreversible inhibitor, with about 17000 mol of product being formed per mol of enzyme inactivated. The half-time of the inhibitory process was about 22 min. With the A-form of the enzyme, the compound had a lower Km value and a considerably lower maximum velocity than the corresponding values obtained with the B-form. Under the conditions used in the present work the inhibition of the A-form of the enzyme was largely reversible.

Full text

PDF
380

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bocchetta A., Piccardi M. P., Del Zompo M., Pintus S., Corsini G. U. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro. J Neurochem. 1985 Sep;45(3):673–676. doi: 10.1111/j.1471-4159.1985.tb04045.x. [DOI] [PubMed] [Google Scholar]
  2. Buckman T. D., Eiduson S. Photoinactivation of B-type monoamine oxidase by a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite. J Biol Chem. 1985 Oct 5;260(22):11899–11902. [PubMed] [Google Scholar]
  3. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., Kopin I. J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546–4550. doi: 10.1073/pnas.80.14.4546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chiba K., Trevor A., Castagnoli N., Jr Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984 Apr 30;120(2):574–578. doi: 10.1016/0006-291x(84)91293-2. [DOI] [PubMed] [Google Scholar]
  5. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M. D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol. 1984 Oct 30;106(1):209–210. doi: 10.1016/0014-2999(84)90700-3. [DOI] [PubMed] [Google Scholar]
  6. Fowler C. J., Tipton K. F. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol. 1981 Dec 15;30(24):3329–3332. doi: 10.1016/0006-2952(81)90607-9. [DOI] [PubMed] [Google Scholar]
  7. Fritz R. R., Abell C. W., Patel N. T., Gessner W., Brossi A. Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett. 1985 Jul 8;186(2):224–228. doi: 10.1016/0014-5793(85)80713-4. [DOI] [PubMed] [Google Scholar]
  8. Fuller R. W., Hemrick-Luecke S. K. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther. 1985 Mar;232(3):696–701. [PubMed] [Google Scholar]
  9. Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984 Oct 4;311(5985):467–469. doi: 10.1038/311467a0. [DOI] [PubMed] [Google Scholar]
  10. Hultborn R., Kjellström B. T., Risberg B. A spectrophotometric method for measuring oxygen consumption in monolayers of cultured endothelial cells. Acta Physiol Scand. 1985 May;124(1):5–10. doi: 10.1111/j.1748-1716.1985.tb07625.x. [DOI] [PubMed] [Google Scholar]
  11. Javitch J. A., Snyder S. H. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol. 1984 Nov 13;106(2):455–456. doi: 10.1016/0014-2999(84)90740-4. [DOI] [PubMed] [Google Scholar]
  12. Kinemuchi H., Arai Y., Toyoshima Y. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. Neurosci Lett. 1985 Jul 31;58(2):195–200. doi: 10.1016/0304-3940(85)90163-6. [DOI] [PubMed] [Google Scholar]
  13. Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. doi: 10.1126/science.6823561. [DOI] [PubMed] [Google Scholar]
  14. Langston J. W., Forno L. S., Rebert C. S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984 Feb 6;292(2):390–394. doi: 10.1016/0006-8993(84)90777-7. [DOI] [PubMed] [Google Scholar]
  15. Langston J. W., Irwin I., Langston E. B., Forno L. S. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 1984 Sep 28;225(4669):1480–1482. doi: 10.1126/science.6332378. [DOI] [PubMed] [Google Scholar]
  16. Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., Herkenham M. A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 1984 Oct 4;311(5985):464–467. doi: 10.1038/311464a0. [DOI] [PubMed] [Google Scholar]
  17. Markwell M. A., Haas S. M., Bieber L. L., Tolbert N. E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978 Jun 15;87(1):206–210. doi: 10.1016/0003-2697(78)90586-9. [DOI] [PubMed] [Google Scholar]
  18. Melamed E., Youdim M. B. Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase. Br J Pharmacol. 1985 Nov;86(3):529–531. doi: 10.1111/j.1476-5381.1985.tb08927.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. OTSUKA S., KOBAYASHI Y. RADIOISOTOPIC ASSAY FOR MONOAMINE OXIDASE DETERMINATIONS IN HUMAN PLASMA. Biochem Pharmacol. 1964 Jul;13:995–1006. doi: 10.1016/0006-2952(64)90096-6. [DOI] [PubMed] [Google Scholar]
  20. Parkinson D., Callingham B. A. The binding of [3H] pargyline to rat liver mitochondrial monoamine oxidase. J Pharm Pharmacol. 1980 Jan;32(1):49–54. doi: 10.1111/j.2042-7158.1980.tb12844.x. [DOI] [PubMed] [Google Scholar]
  21. Powell J. F., Craig I. W. Biochemical and immunological studies of the monoamine-oxidizing activities of cultured human cells. Biochem Soc Trans. 1977;5(1):180–182. doi: 10.1042/bst0050180. [DOI] [PubMed] [Google Scholar]
  22. Rainbow T. C., Parsons B., Wieczorek C. M., Manaker S. Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase. Brain Res. 1985 Mar 25;330(2):337–342. doi: 10.1016/0006-8993(85)90694-8. [DOI] [PubMed] [Google Scholar]
  23. Salach J. I., Singer T. P., Castagnoli N., Jr, Trevor A. Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Commun. 1984 Dec 14;125(2):831–835. doi: 10.1016/0006-291x(84)90614-4. [DOI] [PubMed] [Google Scholar]
  24. Singer T. P., Salach J. I., Castagnoli N., Jr, Trevor A. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases. Biochem J. 1986 May 1;235(3):785–789. doi: 10.1042/bj2350785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. TABOR C. W., TABOR H., ROSENTHAL S. M. Purification of amine oxidase from beef plasma. J Biol Chem. 1954 Jun;208(2):645–661. [PubMed] [Google Scholar]
  26. Tatsunami S., Yago N., Hosoe M. Kinetics of suicide substrates. Steady-state treatments and computer-aided exact solutions. Biochim Biophys Acta. 1981 Dec 15;662(2):226–235. doi: 10.1016/0005-2744(81)90034-6. [DOI] [PubMed] [Google Scholar]
  27. Tipton K. F. Determination of monoamine oxidase. Methods Find Exp Clin Pharmacol. 1985 Jul;7(7):361–367. [PubMed] [Google Scholar]
  28. Tipton K. F., Fowler C. J., McCrodden J. M., Strolin Benedetti M. The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Biochem J. 1983 Jan 1;209(1):235–242. doi: 10.1042/bj2090235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Waldmeier P. C., Felner A. E., Tipton K. F. The monoamine oxidase inhibiting properties of CGP 11305 A. Eur J Pharmacol. 1983 Oct 14;94(1-2):73–83. doi: 10.1016/0014-2999(83)90443-0. [DOI] [PubMed] [Google Scholar]
  30. Waley S. G. Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J. 1985 May 1;227(3):843–849. doi: 10.1042/bj2270843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Waley S. G. Kinetics of suicide substrates. Biochem J. 1980 Mar 1;185(3):771–773. doi: 10.1042/bj1850771. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES